A new model of induced experimental systemic lupus erythematosus (SLE) in pigs and its amelioration by treatment with a tolerogenic peptide

Journal of Clinical Immunology

Volumn 30, Issue 1, 2010, Pages 34-44

  Sharabi, Amir ^a   Dayan, Molly ^a   Zinger, Heidy ^a   Mozes, Edna ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Experimental SLE in pigs; Glomerular immune complex deposits; Immunomodulation of gene expression; Peptide therapy

Indexed keywords

AUTOANTIBODY; GAMMA INTERFERON; GLYCYLTYROSYLTYROSYLTRYPTOPHYLSERYLTRYPTOPHYLISOLEUCYL ARGINYLGLUTAMINYLPROLYLPROLYLGLYCYLLYSYLGLYCYLGLUTAMYLGLUTAMYL TRYPTOPHYLISOLEUCYLGLYCINE; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; PROTEIN BCL XL; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE COMPARISON; EXPERIMENTAL MODEL; FEMALE; GENE EXPRESSION; KIDNEY BIOPSY; NONHUMAN; PRIORITY JOURNAL; SWINE; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; BCL-X PROTEIN; CELLS, CULTURED; COMPLEMENTARITY DETERMINING REGIONS; CYTOKINES; DISEASE MODELS, ANIMAL; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HUMANS; IMMUNE TOLERANCE; IMMUNOMODULATION; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; PEPTIDE FRAGMENTS; SWINE;

EID: 77249141746     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-009-9326-4     Document Type: Article

References (52)

1. Hahn BH. Overview of pathogenesis of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubious' lupus erythematosus. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 46-53.
2. G Nagy A Koncz A Perl 2005 T- and B-cell abnormalities in systemic lupus erythematosus Crit Rev Immunol 25 123 140 10.1615/CritRevImmunol.v25.i2.30 15952933 1:CAS:528:DC%2BD2sXktlCgsbs%3D (Pubitemid 40910585)
3. Theofilopoulos A. Murine models of lupus. In: Lahita RG, editor. Systemic lupus erythematosus. New York: Churchill Livingston; 1992. p. 121-94.
4. S Mendlovic S Brocke Y Shoenfeld M Ben Basat A Meshorer R Bakimer 1988 Induction of a systemic lupus erythematosus like disease in mice by a common human anti-DNA idiotype Proc Natl Acad Sci U S A 85 2260 2264 10.1073/pnas.85.7.2260 3258423 1:CAS:528:DyaL1cXhvVGjs7k%3D (Pubitemid 24315870)
5. A Waisman S Mendlovic JP Ruiz H Zinger A Meshorer E Mozes 1993 The role of the 16/6 idiotype network in the induction and manifestations of systemic lupus erythematosus Int Immunol 5 1293 1300 10.1093/intimm/5.10.1293 8268135 1:CAS:528:DyaK2cXivFaitQ%3D%3D
6. A Waisman E Mozes 1993 Variable regions of autoantibodies isolated from mice with experimental systemic lupus erythematosus Eur J Immunol 23 1566 1573 10.1002/eji.1830230726 8325334 1:CAS:528:DyaK3sXmtVWnsrY%3D (Pubitemid 23218066)
7. A Waisman PJ Ruiz E Israeli E Eilat S K̂nen-Waisman H Zinger, et al. 1997 Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody Proc Natl Acad Sci U S A 94 4620 4625 10.1073/pnas.94.9.4620 9114040 1:CAS:528:DyaK2sXjtVymtbs%3D (Pubitemid 27194292)
8. E Eilat H Zinger A Nyska E Mozes 2000 Prevention of systemic lupus erythematosus-like disease in (NZBxNZW)F1 mice by treating with CDR1- and CDR3-based peptides of a pathogenic autoantibody J Clin Immunol 20 268 278 10.1023/A:1006663519132 10939714 1:CAS:528:DC%2BD3cXlvVOlsLk%3D (Pubitemid 30619398)
9. E Eilat M Dayan H Zinger E Mozes 2001 The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus Proc Natl Acad Sci U S A 98 1148 1153 10.1073/pnas.98.3.1148 11158609 1:CAS:528:DC%2BD3MXht1Smtro%3D (Pubitemid 32121201)
10. H Zinger E Eilat A Meshorer E Mozes 2003 Peptides based on the complementarity-determining regions of a pathogenic autoantibody mitigate lupus manifestations of (NZBxNZW)F1 mice via active suppression Int Immunol 15 205 214 10.1093/intimm/dxg026 12578850 1:CAS:528:DC%2BD3sXitFKls78%3D (Pubitemid 36267112)
11. A Waisman Y Shoenfeld M Blank PJ Ruiz E Mozes 1995 The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment Int Immunol 7 689 696 10.1093/intimm/7.4. 689 7547696 1:CAS:528:DyaK2MXlsF2nsrw%3D
12. D Luger M Dayan H Zinger J-P Liu E Mozes 2004 A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation J Clin Immunol 24 579 590 10.1007/s10875-004-6245-2 15622442 1:CAS:528:DC%2BD2MXhtFSnuw%3D%3D (Pubitemid 40933109)
13. R Parameswarran H Ben David A Sharabi H Zinger E Mozes 2009 B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus Clin Immunol 131 223 232 10.1016/j.clim.2008.12.009 1:CAS:528:DC%2BD1MXksVWgtL0%3D
14. MJ Rapoport A Sharabi D Aharoni O Bloch H Zinger M Dayan, et al. 2005 Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase Clin Immunol 117 262 270 10.1016/j.clim.2005.09. 003 16257268 1:CAS:528:DC%2BD2MXhtlGlsrzN (Pubitemid 43005212)
15. A Sharabi D Luger H Ben-David M Dayan H Zinger E Mozes 2007 The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model J Immunol 179 4979 4987 17911582 1:CAS:528:DC%2BD2sXhtFWitr3E
16. A Sharabi H Zinger M Zborowsky ZM Sthoeger E Mozes 2006 A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-β Proc Natl Acad Sci U S A 103 8810 8815 10.1073/pnas.0603201103 16735466 1:CAS:528:DC%2BD28XlvVChsrw%3D (Pubitemid 43878101)
17. A Sharabi E Mozes 2008 The suppression of murine lupus by a tolerogenic peptide involves Foxp3-expressing CD8 cells that are required for the optimal induction and function of Foxp3-expressing CD4 cells J Immunol 181 3243 3251 18713995 1:CAS:528:DC%2BD1cXhtVSiu7jJ
18. ZM Sthoeger M Dayan A Tcherniack L Green S Toledo R Segal, et al. 2003 Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies Clin Exp Immunol 131 385 392 10.1046/j.1365-2249.2003. 02058.x 12562403 1:CAS:528:DC%2BD3sXhs12itLo%3D (Pubitemid 36205154)
19. N Mauermann Z Sthoeger H Zinger E Mozes 2004 Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients Clin Exp Immunol 137 513 520 10.1111/j.1365-2249.2004.02559.x 15320900 1:CAS:528:DC%2BD2cXnvFKjtb8%3D (Pubitemid 39128077)
20. ZM Sthoeger A Sharabi M Dayan H Zinger I Asher U Sela, et al. 2009 The tolerogenic peptide, hCDR1, down-regulates pathogenic cytokines and apoptosis and up-regulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients Hum Immunol 70 139 145 10.1016/j.humimm.2009.01.018 19280712 1:CAS:528:DC%2BD1MXivVWhsro%3D
21. AD Kirk 2003 Crossing the bridge: large animal models in translational transplantation research Immunol Rev 196 176 196 10.1046/j.1600-065X.2003.00081. x 14617205 1:CAS:528:DC%2BD3sXhtVSlsLvJ (Pubitemid 37468111)
22. A Saalmüller T Werner V Fachinger 2002 T-helper cells from naive to committed Veterinary Immunol Immunopathol 87 137 145 10.1016/S0165-2427(02) 00045-4 (Pubitemid 34665232)
23. Rodrìguez-Carreòo L Lûpez-Fuertes C Revilla A Ezquerra F Alonso J Domìnguez 2002 Phenotypic characterization of porcine IFN-producing lymphocytes by flow cytometry J Immunol Methods 259 171 179 10.1016/S0022-1759(01)00511-7 (Pubitemid 33124394)
24. G Riemekasten BH Hahn 2005 Key autoantigens in SLE Rheumatology 44 975 982 10.1093/rheumatology/keh688 15901907 1:CAS:528:DC%2BD2MXmsV2isLw%3D (Pubitemid 41487168)
25. CC Mok CS Lau 2003 Pathogenesis of systemic lupus erythematosus J Clin Pathol 56 481 490 10.1136/jcp.56.7.481 12835292 1:STN:280:DC%2BD3szgslCjuw%3D%3D (Pubitemid 36819418)
26. P Kuo MS Bynoe C Wang B Diamond 1999 Bcl-2 leads to expression of anti-DNA B cells but no nephritis: a model for a clinical subset Eur J Immunol 29 3168 3178 10.1002/(SICI)1521-4141(199910)29:10<3168::AID-IMMU3168>3.0. CO;2-H 10540328 1:CAS:528:DyaK1MXmslOmtrs%3D (Pubitemid 29484207)
27. M Dayan H Zinger F Kalush G Mor Y Amir-Zaltzman F Kohen, et al. 1997 The beneficial effects of treatment with tamoxifen and anti-oestradiol antibody on experimental systemic lupus erythematosus are associated with cytokine modulations Immunology 90 101 108 10.1046/j.1365-2567.1997.00122.x 9038719 1:CAS:528:DyaK2sXjsFarsg%3D%3D
28. R Segal M Dayan H Zinger E Mozes 1995 Methotrexate treatment in murine experimental systemic lupus erythematosus (SLE); clinical benefits associated with cytokine manipulation Clin Exp Immunol 101 66 72 7621594 1:CAS:528:DyaK2MXnsF2kur8%3D
29. JP Seery V Cattell FM Watt 2001 Cutting edge: amelioration of kidney disease in a transgenic mouse model of lupus nephritis by administration of the caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl-(β-o-methyl)-flu- oromethylketone J Immunol 167 2452 2455 11509582 1:CAS:528:DC%2BD3MXmtlSjsLc%3D
30. A Sharabi A Haviv H Zinger M Dayan E Mozes 2006 Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosis Clin Immunol 119 146 155 10.1016/j.clim.2006.01.007 16503419 1:CAS:528:DC%2BD28XjsFOgs7w%3D
31. DA Horwitz CO Jacob 1994 The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications Springer Semin Immunopathol 16 181 200 10.1007/BF00197516 7716704 1:CAS:528: DyaK2MXksFaqurs%3D
32. AN Theofilopoulos BR Lawson 1999 Tumour necrosis factor and other cytokines in murine lupus Ann Rheum Dis 58 Suppl 1 I49 55 10.1136/ard.58.2008. i49 10577973 1:CAS:528:DC%2BD3cXivFGksw%3D%3D
33. R Segal BL Bermas M Dayan F Kalush GM Shearer E Mozes 1997 Kinetics of cytokine production in experimental systemic lupus erythematosus: involvement of T helper cell 1/T helper cell 2-type cytokines in disease J Immunol 158 3009 3016 9058840 1:CAS:528:DyaK2sXhvVyjsL8%3D
34. GS Dean J Tyrrell-Price E Crawley DA Isenberg 2000 Cytokines and systemic lupus erythematosus Ann Rheum Dis 59 243 251 10.1136/ard.59.4.243 10733469 1:CAS:528:DC%2BD3cXivFajtr4%3D (Pubitemid 30305564)
35. MJ Kaplan 2004 Apoptosis in systemic lupus erythematosus Clin Immunol 112 210 218 10.1016/j.clim.2004.04.007 15308111 1:CAS:528:DC%2BD2cXmslOhu7g%3D (Pubitemid 39078693)
36. H Trébéden-Nègre B Weill C Fournier F Batteux 2003 B cell apoptosis accelerates the onset of murine lupus Eur J Immunol 33 1603 1612 10.1002/eji.200323665 12778478 1:CAS:528:DC%2BD3sXkvF2rtLc%3D (Pubitemid 36790421)
37. W Emlen J Niebur R Kadera 1994 Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus J Immunol 152 3685 3692 8144943 1:STN:280:DyaK2c7psVWgsg%3D%3D
38. Ben-David H, Sharabi A, Parameswaran R, Zinger H, Mozes E. A tolerogenic peptide down-regulates mature B cells in bone marrow of lupus-afflicted mice by inhibition of IL-7, leading to apoptosis. Immunology. 2009;doi: 10.1111/j.1365-2567.2009.03109.x.
39. Sharabi A, Lapter S, Mozes E. Bcl-xL is required for the development of functional regulatory CD4 cells in lupus-afflicted mice following treatment with a tolerogenic peptide. J Autoimmun. 2009;doi: 10.1016/j.jaut.2009.06.002.
40. K Ohtsuka JD Gray MM Stimmler B Toro DA Horwitz 1998 Decreased production of TGF-beta by lymphocytes from patients with systemic lupus erythematosus J Immunol 160 2539 2545 9498800 1:CAS:528:DyaK1cXhtlCmtrY%3D
41. L Yaswen AB Kulkarni T Fredrickson B Mittleman R Schiffman S Payne, et al. 1996 Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse Blood 87 1439 1445 8608234 1:CAS:528:DyaK28XhtVGnur0%3D
42. S Sakaguchi 2004 Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses Annu Rev Immunol 22 531 562 10.1146/annurev.immunol.21.120601.141122 15032588 1:CAS:528:DC%2BD2cXktlOgsLo%3D (Pubitemid 38680433)
43. S Paust H Cantor 2005 Regulatory T cells and autoimmune disease Immunol Rev 204 195 207 10.1111/j.0105-2896.2005.00247.x 15790360 1:CAS:528: DC%2BD2MXkslGns7Y%3D (Pubitemid 40460503)
44. DA Horwitz 2008 Regulatory T cells in systemic lupus erythematosus: past, present and future Arthritis Res Ther 10 227 10.1186/ar2511 19040771 1:CAS:528:DC%2BD1cXhsFeis7fF
45. SC Lin KH Chen CH Lin CC Kuo QD Ling CH Chan 2007 The quantitative analysis of peripheral blood FOXP3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients Eur J Clin Invest 37 987 996 10.1111/j.1365-2362.2007.01882.x 18036033 1:CAS:528:DC%2BD1cXlslCktw%3D%3D (Pubitemid 350151184)
46. A Sharabi H Azulai ZM Sthoeger E Mozes 2007 Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action Immunology 121 248 257 10.1111/j.1365-2567.2007.02565.x 17346282 1:CAS:528:DC%2BD2sXmt1eqs7c%3D (Pubitemid 46663093)
47. A La Cava FM Ebling BH Hahn 2004 Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand Black × New Zealand White) F1 mice suppress in vitro production of antibodies to DNA J Immunol 173 3542 3548 15322219
48. BH Hahn M Anderson E Le A La Cava 2008 Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients Arthritis Rheum 58 2488 2497 10.1002/art.23609 18668553 1:CAS:528:DC%2BD1cXhtVCjur7N
49. HK Kang MA Michaels BR Berner SK Datta 2005 Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets J Immunol 174 3247 3255 15749855 1:CAS:528:DC%2BD2MXitVehsrs%3D
50. HK Kang M Liu SK Datta 2007 Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells J Immunol 178 7849 7858 17548623 1:CAS:528:DC%2BD2sXmtVKnsrk%3D
51. U Sela A Sharabi M Dayan R Hershkoviz E Mozes 2008 The role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine models Immunology 128 e395 e405 10.1111/j.1365-2567.2008.02988.x 19040426
52. ZM Sthoeger A Sharabi Y Molad I Asher H Zinger M Dayan, et al. 2009 Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression J Autoimmun 33 77 82 10.1016/j.jaut.2009.03. 009 19346102 1:CAS:528:DC%2BD1MXms1Wgu70%3D